Drugs / Gefitinib
Gefitinib
also known as
Iressa · ZD1839 · Gefitinib (Iressa) · Iressa TM · CTTQ · GEF · Gefitinib mylan · GFT · +3 more
Small molecule targets EGFR via inhibition
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed non-small cell lung carcinoma 1 milestone | |||||
| Filed | US (FDA) | IRESSA | non-small cell lung carcinoma | 2014-12-02 | “FDA has accepted for filing the New Drug Application (NDA) for IRESSA® (gefitinib)” astrazeneca.com ↗ “Iressa: NDA accepted.” astrazeneca.com ↗ |
| Approved Indication not stated 2 milestones | |||||
| Approved | EU (EMA) | Iressa | — | 2009-06-24 | europa.eu ↗ |
| Approved | US (FDA) | IRESSA | — | 2003-05-05 | fda.gov ↗ |
Trials 283 · started per year
today
US approved 2003
EU approved 2009
1
4
18
25
43
47
24
9
5
4
8
4
7
9
7
14
9
10
11
9
4
3
1
3
199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07458919 | Mar 2026 → Oct 2030 expected | lung cancer | Fuzhou General Hospital | Not yet recruiting | No outcome recorded |
| Phase 129 trials | ||||||
| Phase 1 | NCT04390984 | May 2020 → Feb 2021 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03599518 | Sep 2018 → Apr 2020 | non-small cell lung carcinoma | Daiichi Sankyo | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03333343 | Jan 2018 → Oct 2026 expected | non-small cell lung carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02374645 | Apr 2015 → Feb 2018 | non-small cell lung carcinoma | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT02151721 | Jun 2014 → Feb 2018 | non-small cell lung carcinoma | Kanazawa University | Unknown | No outcome recorded |
| Phase 1 | NCT02088112 | Mar 2014 → Mar 2021 | non-small cell lung carcinoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT02040064 | Jan 2014 → Mar 2016 | non-small cell lung carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Completed | No outcome recorded |
| Phase 1 | NCT01570296 | Oct 2011 → Feb 2016 | non-small cell lung carcinoma | National Cancer Centre, Singapore | Completed | No outcome recorded |
| Phase 1 | NCT00497250 | Jul 2007 → Mar 2009 | non-small cell lung carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 1 | NCT00372515 | Jun 2006 → Dec 2012 | non-small cell lung carcinoma | David M. Jackman, MD | Completed | No outcome recorded |
| Phase 1 | NCT00290719 | Nov 2005 → Apr 2008 | esophageal cancer | University of California, San Francisco | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00132158 | Sep 2005 → Oct 2011 | glioblastoma, neuroblastoma, osteosarcoma, rhabdomyosarcoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00127829 | Jul 2005 → Jan 2008 | neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00162318 | Mar 2005 → Apr 2006 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00820417 | Jun 2004 → Sep 2007 | colorectal cancer, head and neck cancer, non-small cell lung carcinoma | Harrison Clinical Research | Completed | No outcome recorded |
| Phase 1 | NCT00083057 | May 2004 → Oct 2010 | head and neck cancer | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT00255489 | May 2004 → Jun 2006 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00084786 | Mar 2004 → Jul 2006 | cancer of unknown primary site | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00681967 | Feb 2004 → Oct 2009 | head and neck cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00328562 | Dec 2003 → Apr 2008 | non-small cell lung carcinoma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1 | NCT00186979 | May 2003 → Mar 2010 | cancer | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00252798 | Jul 2002 → Oct 2005 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00040781 | Jun 2002 → Oct 2004 | childhood malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00185835 | Jun 2002 → Jul 2006 | head and neck cancer, squamous cell carcinoma | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT00039390 | Apr 2002 → May 2007 | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00033449 | Feb 2002 → Apr 2010 | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, lip and oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00027625 | Jan 2002 → Mar 2005 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1 | NCT00026364 | Nov 2001 → Dec 2006 | colorectal cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00005806 | Sep 1999 → Mar 2002 | lung cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/231 trials · 2 missed | ||||||
| Phase 1/2 | NCT06071013 | Feb 2024 → Aug 2026 overdue | non-small cell lung carcinoma | China Medical University Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03122717 | May 2017 → Oct 2026 expected | non-small cell lung carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03758287 | Nov 2016 → Sep 2021 | non-small cell lung carcinoma | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT02039674 | Feb 2014 → Nov 2016 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 1/2 | NCT01982955 | Dec 2013 → Dec 2017 | non-small cell lung carcinoma | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1/2 | NCT01513174 | Aug 2011 → Jul 2016 | non-small cell lung carcinoma | Spanish Lung Cancer Group | Completed | Missed primary |
| Phase 1/2 | NCT01027676 | Jun 2010 → Dec 2013 | non-small cell lung carcinoma | National Cancer Center, Korea | Unknown | No outcome recorded |
| Phase 1/2 | NCT00809237 | Nov 2008 → Nov 2014 | non-small cell lung carcinoma | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 1/2 | NCT00423397 | Sep 2006 → Jan 2008 | skin cancer | University of California, San Diego | Unknown | No outcome recorded |
| Phase 1/2 | NCT00352105 | Apr 2006 → Sep 2008 | head and neck cancer | David Adelstein | Completed | No outcome recorded |
| Phase 1/2 | NCT00113529 | Oct 2004 → Sep 2007 | renal cell carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1/2 | NCT00098462 | Oct 2004 → ? | lung cancer | Jonsson Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00317772 | Sep 2004 → Nov 2020 | fallopian tube cancer, ovarian cancer, peritoneal neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00096486 | May 2004 → Jul 2010 | lung cancer | Memorial Sloan Kettering Cancer Center | Completed | Missed primary |
| Phase 1/2 | NCT00238628 | Apr 2004 → Apr 2005 | lung cancer | Stanford University | Completed | No outcome recorded |
| Phase 1/2 | NCT00195078 | Apr 2004 → Sep 2006 | head and neck cancer | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 1/2 | NCT00085566 | Mar 2004 → Feb 2008 | central nervous system neoplasm, prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00242788 | Feb 2004 → Nov 2005 | colorectal cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1/2 | NCT00087334 | Jan 2004 → Nov 2005 | colorectal cancer | Roswell Park Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00086957 | Jan 2004 → Aug 2015 | breast cancer | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00212108 | Nov 2003 → Mar 2007 | nasopharyngeal carcinoma | National University Hospital, Singapore | Completed | No outcome recorded |
| Phase 1/2 | NCT00237900 | Jul 2003 → Feb 2004 | microinvasive gastric cancer | AstraZeneca | Terminated | No outcome recorded |
| Phase 1/2 | NCT00239304 | Jun 2003 → Mar 2006 | head and neck neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1/2 | NCT00062270 | May 2003 → Sep 2004 | lung cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 1/2 | NCT00093652 | May 2003 → May 2006 | esophageal cancer | Roswell Park Cancer Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT00239291 | Jan 2003 → May 2006 | prostate cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1/2 | NCT00234416 | Aug 2002 → Mar 2005 | malignant pancreatic neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1/2 | NCT00042991 | Jul 2002 → Feb 2010 | anaplastic astrocytoma, anaplastic oligodendroglioma, childhood brain stem glioma, childhood oligodendroglioma +2 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00052208 | Mar 2002 → Jun 2005 | adult glioblastoma, giant cell glioblastoma, gliosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00026299 | Sep 2001 → Dec 2002 | colorectal cancer | University of Chicago | Completed | No outcome recorded |
| Phase 1/2 | NCT00268255 | — | non-small cell lung carcinoma | Barbara Ann Karmanos Cancer Institute | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2161 trials · 4 met primary · 9 missed | ||||||
| Phase 2 | NCT07829926 | Nov 2026 expected | hepatocellular carcinoma | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07477457 | Mar 2026 → Mar 2028 expected | metastatic neoplasm, osteosarcoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04358562 | May 2020 → May 2022 | non-small cell lung carcinoma | Second Affiliated Hospital of Nanchang University | Unknown | No outcome recorded |
| Phase 2 | NCT04193007 | Dec 2019 → Dec 2021 | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Second Affiliated Hospital of Nanchang University | Unknown | No outcome recorded |
| Phase 2 | NCT03944772 | Jun 2019 → May 2025 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03720873 | Oct 2018 → Jun 2021 | — | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03486496 | Jun 2018 → Jun 2019 | lung adenocarcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03457337 | Mar 2018 → Oct 2020 | — | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03382795 | Jan 2018 → Mar 2023 | non-small cell lung carcinoma | Korea University Guro Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03292133 | Oct 2017 → Dec 2021 | lung cancer | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Show all 161 trials opens the full record — a long page | ||||||
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT02326285 | Nov 2015 → Mar 2017 | non-small cell lung carcinoma | AIO-Studien-gGmbH | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT02338011 | Nov 2014 → Nov 2017 | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Shanghai Chest Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT01579630 | Mar 2011 → Jun 2013 | non-small cell lung carcinoma | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 2/3 | NCT01769066 | Dec 2009 → Feb 2014 | non-small cell lung carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 2/3 | NCT00259064 | Sep 2004 → Feb 2007 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2/3 | NCT00234429 | Nov 2003 → Jun 2006 | colorectal cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 335 trials · 5 met primary · 5 missed | ||||||
| Phase 3 | NCT04143607 | Jul 2019 → Mar 2024 overdue | — | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Active not recruiting | Met primary |
| Phase 3 | NCT03656393 | Aug 2018 → Jul 2020 | non-small cell lung carcinoma | Shenzhen People's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03381066 | Apr 2018 → Dec 2022 | — | Yonsei University | Unknown | No outcome recorded |
| Phase 3 | NCT03203590 | Sep 2017 → Jan 2026 | — | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT02929693 | Oct 2016 → Jun 2019 | cancer | Shanghai University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 3 | NCT02859077 | Aug 2016 → Jul 2017 | non-small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | No outcome recorded |
| Phase 3 | NCT01951469 | Jan 2016 → Jun 2022 | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Sun Yat-sen University | Unknown | Met primary |
| Phase 3 | NCT02714010 | Aug 2015 → Dec 2021 | non-small cell lung carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT02411448 | May 2015 → Jan 2019 overdue | non-small cell lung carcinoma | Eli Lilly and Company | Active not recruiting | Met primary |
| Phase 3 | NCT02518802 | Jan 2015 → Jan 2018 | lung neoplasm | Tang-Du Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01544179 | Mar 2012 → May 2014 | non-small cell lung carcinoma | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT01405079 | Sep 2011 → Mar 2017 | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Unknown | Met primary |
| Phase 3 | NCT01404260 | Jun 2011 → Mar 2015 | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Completed | No outcome recorded |
| Phase 3 | NCT00807066 | Nov 2008 → Nov 2009 | non-small cell lung carcinoma | Fondazione Humanitas per la Ricerca | Completed | No outcome recorded |
| Phase 3 | NCT01066195 | May 2008 → Oct 2010 | non-small cell lung carcinoma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00322452 | Mar 2006 → Apr 2008 | non-small cell lung carcinoma | AstraZeneca | Completed | Met primary |
| Phase 3 | NCT00090675 | Jan 2006 → Nov 2007 | non-small cell lung carcinoma | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 3 | NCT00455936 | Oct 2005 → Nov 2009 | lung cancer | National Cancer Center, Korea | Completed | No outcome recorded |
| Phase 3 | NCT00478049 | Sep 2005 → May 2007 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00357734 | Jan 2005 → May 2015 | breast cancer, lung cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00088907 | Aug 2004 → May 2009 | head and neck cancer | National Cancer Institute (NCI) | Terminated | Missed primary |
| Phase 3 | NCT00091156 | May 2004 → Jul 2008 | lung cancer | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT00076388 | Feb 2004 → Mar 2007 | non-small cell lung carcinoma | AstraZeneca | Completed | Mixed |
| Phase 3 | NCT00234468 | Jan 2004 → Aug 2007 | non-small cell lung carcinoma | AstraZeneca | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00206219 | Nov 2003 → Sep 2007 | head and neck squamous cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00252707 | Sep 2003 → Nov 2006 | non-small cell lung carcinoma | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT00242801 | Jul 2003 → Apr 2005 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00144066 | Jan 2003 → ? | lung cancer | West Japan Thoracic Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00049543 | Sep 2002 → Apr 2011 | adenosquamous lung carcinoma, lung adenocarcinoma, lung large cell carcinoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 3 | NCT00020709 | Jun 2001 → Feb 2007 | lung adenocarcinoma, lung large cell carcinoma, squamous cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00034879 | Aug 2000 → Oct 2003 | metastatic carcinoma, non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00006049 | May 2000 → ? | lung cancer | AstraZeneca | Unknown | No outcome recorded |
| Phase 3 | NCT00006048 | May 2000 → ? | lung cancer | AstraZeneca | Unknown | No outcome recorded |
| Phase 3 | NCT00635973 | Feb 2000 → Oct 2003 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00080340 | ? → May 2005 | non-small cell lung carcinoma | Telik | Completed | No outcome recorded |
| Phase 47 trials · 2 met primary | ||||||
| Phase 4 | NCT03264794 | Aug 2017 → Dec 2021 | non-small cell lung carcinoma | Jiangsu Famous Medical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT02299765 | Dec 2014 → Oct 2017 | non-small cell lung carcinoma | Sichuan University | Terminated | No outcome recorded |
| Phase 4 | NCT02031601 | Jan 2014 → Dec 2016 | non-small cell lung carcinoma | Qilu Hospital of Shandong University | Unknown | Met primary |
| Phase 4 | NCT01203917 | Sep 2010 → Aug 2012 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00770588 | Sep 2008 → Jan 2011 | non-small cell lung carcinoma | AstraZeneca | Completed | Met primary |
| Phase 4 | NCT00536107 | Oct 2007 → Aug 2009 | non-small cell lung carcinoma | AstraZeneca | Terminated | No outcome recorded |
| Phase 4 | NCT00608868 | Jan 2007 → Jan 2009 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT04642547 | Dec 2020 → Mar 2023 | hepatocellular carcinoma | RenJi Hospital | Completed | No outcome recorded |
| — | NCT03766490 | Mar → Dec 2019 | non-small cell lung carcinoma | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| — | NCT03381430 | Jun 2018 → Mar 2023 | lung cancer | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| — | NCT03258671 | Oct 2017 → Dec 2020 | non-small cell lung carcinoma | LuBing | Unknown | No outcome recorded |
| — | NCT02551718 | Sep 2015 → Jun 2020 | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia | University of Washington | Completed | No outcome recorded |
| — | NCT02282267 | Oct 2014 → Dec 2017 | lung adenocarcinoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| — | NCT02148380 | May → Dec 2014 | non-small cell lung carcinoma | Baohui Han | Completed | No outcome recorded |
| — | NCT02013089 | Dec 2013 → May 2017 | digestive system cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT03157310 | May 2009 → May 2013 | non-small cell lung carcinoma | Qilu Hospital of Shandong University | Completed | No outcome recorded |
| — | NCT00104728 | Oct 2004 → May 2008 | lung cancer | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00068497 | Aug 2003 → Dec 2007 | adenoid cystic carcinoma, carcinoma of lip, esthesioneuroblastoma, hypopharynx squamous cell carcinoma +19 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT00684385 | — | head and neck cancer, non-small cell lung carcinoma | AstraZeneca | Approved for marketing | No outcome recorded |
| — | NCT00683306 | — | non-small cell lung carcinoma | AstraZeneca | Approved for marketing | No outcome recorded |
| Comparator or background therapy66 trials | ||||||
| Phase 1 | NCT07271446 Background | Sep 2018 → Aug 2019 | non-small cell lung carcinoma | Precision Biotech Taiwan Corp. | Completed | No outcome recorded |
| Phase 1 | NCT03050411 Background | May 2016 → Jun 2019 | non-small cell lung carcinoma | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02321293 Background | Aug 2015 → Aug 2016 | lung cancer | Lady Davis Institute | Unknown | No outcome recorded |
| Phase 1 | NCT01602289 Background | Jun 2012 → Aug 2014 | lymphoma, non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01147211 Background | Sep 2010 → Jul 2013 | non-small cell lung carcinoma | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT00502060 Background | Aug 2004 → Jun 2006 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00310154 Background | Nov 2003 → Jul 2007 | lung cancer | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 1 | NCT00084708 Background | Nov 2002 → Oct 2006 | cancer of unknown primary site | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT03799094 Background | Dec 2018 → Dec 2020 | non-small cell lung carcinoma | Clifford Hospital, Guangzhou, China | Unknown | No outcome recorded |
| Phase 1/2 | NCT02906163 Background | Oct 2016 → Dec 2019 | lung cancer | SciClone Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT01039948 Comparator | Dec 2009 → Aug 2013 | non-small cell lung carcinoma | AVEO Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 2 | NCT04425187 Comparator | Jun 2020 → Dec 2021 | — | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT03389256 Background | Dec 2018 → Dec 2020 | non-small cell lung carcinoma | Sichuan Cancer Hospital and Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03461185 Background | May 2018 → Aug 2019 | non-small cell lung carcinoma | Xinqiao Hospital of Chongqing | Unknown | No outcome recorded |
| Phase 2 | NCT03119519 Background | Dec 2017 → Sep 2020 | non-small cell lung carcinoma | Southern Medical University, China | Unknown | No outcome recorded |
| Phase 2 | NCT03123484 Background | Apr 2017 → Apr 2019 | non-small cell lung carcinoma | China Medical University, China | Unknown | No outcome recorded |
| Phase 2 | NCT03595644 Background | Feb 2017 → Jun 2019 | non-small cell lung carcinoma | Tongji Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03002844 Background | Dec 2016 → Aug 2017 | non-small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | No outcome recorded |
| Phase 2 | NCT02788058 Background | May 2016 → May 2021 | lung adenocarcinoma | First People's Hospital of Hangzhou | Unknown | No outcome recorded |
| Phase 2 | NCT02787447 Background | May 2016 → Dec 2017 | lung adenocarcinoma | First People's Hospital of Hangzhou | Unknown | No outcome recorded |
| Phase 2 | NCT01864681 Background | May 2013 → Dec 2017 | cancer of unknown primary site, non-small cell lung carcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Completed | No outcome recorded |
| Phase 2 | NCT01556191 Background | May 2012 → May 2018 | — | French Cooperative Thoracic Intergroup | Completed | Met primary |
| Phase 2 | NCT01610336 Background | Apr 2012 → Jun 2016 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01502202 Comparator | Mar 2012 → Aug 2014 | adenocarcinoma, non-small cell lung carcinoma | National Cancer Center, Korea | Unknown | No outcome recorded |
| Phase 2 | NCT01466660 Comparator | Dec 2011 → Apr 2016 | lung neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT01498562 Comparator | Dec 2011 → Jun 2014 | non-small cell lung carcinoma | Yonsei University | Completed | Missed primary |
| Phase 2 | NCT01310855 Comparator | May 2011 → May 2013 | glioblastoma | University College, London | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00891579 Comparator | Feb 2009 → Sep 2012 | non-small cell lung carcinoma | Chinese Society of Lung Cancer | Completed | No outcome recorded |
| Phase 2 | NCT01783834 Comparator | Feb 2008 → Jun 2014 | — | Gachon University Gil Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01037998 Comparator | Nov 2005 → Dec 2009 | non-small cell lung carcinoma | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| Phase 2 | NCT00238251 Comparator | May 2005 → Apr 2009 | lung cancer, metastatic malignant neoplasm | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00479089 Comparator | Feb 2004 → Aug 2014 | urinary bladder cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00077025 Comparator | Jan 2004 → May 2013 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00080743 Comparator | Jan 2004 → Apr 2005 | breast cancer | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00025675 Comparator | Oct 2001 → Jul 2006 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2/3 | NCT03653546 Comparator | Oct 2018 → Jul 2022 | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Alpha Biopharma (Jiangsu) Co., Ltd. | Completed | Met primary |
| Phase 2/3 | NCT02387086 Background | May 2015 → May 2017 | non-small cell lung carcinoma | Bai Jun | Unknown | No outcome recorded |
| Phase 3 | NCT03866499 Comparator | Apr 2021 → Nov 2023 overdue | non-small cell lung carcinoma | Beta Pharma Shanghai | Active not recruiting | Met primary |
| Phase 3 | NCT04248829 Comparator | Feb 2020 → Jul 2022 | non-small cell lung carcinoma | Yuhan Corporation | Completed | Met primary |
| Phase 3 | NCT04239833 Comparator | Jan 2020 → Jan 2022 | non-small cell lung carcinoma | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03787992 Comparator | May 2019 → Sep 2021 overdue | — | Allist Pharmaceuticals, Inc. | Active not recruiting | Met primary |
| Phase 3 | NCT04028778 Background | Apr 2019 → Dec 2020 | non-small cell lung carcinoma | Sun Yat-sen University | Unknown | Met primary |
| Phase 3 | NCT03856697 Comparator | Mar 2019 → Mar 2022 | non-small cell lung carcinoma | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03849768 Comparator | Feb 2019 → Jan 2021 | non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | Met primary |
| Phase 3 | NCT03529084 Comparator | Jul 2018 → Aug 2020 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT02824458 Background | Jun 2016 → Dec 2023 | — | Sun Yat-sen University | Unknown | Met primary |
| Phase 3 | NCT02588261 Comparator | Feb 2016 → Dec 2017 | non-small cell lung carcinoma | Astellas Pharma Global Development, Inc. | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT02893332 Background | Jan 2016 → Aug 2020 | lung cancer susceptibility 4 | Sichuan Provincial People's Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT02882984 Background | Mar 2015 → Mar 2020 | — | Sichuan Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02296125 Comparator | Dec 2014 → Jun 2017 | — | AstraZeneca | Completed | Met primary |
| Phase 3 | NCT01774721 Comparator | May 2013 → Jul 2016 | lung cancer | Pfizer | Completed | Met primary |
| Phase 3 | NCT02889692 Background | Mar 2013 → Dec 2016 | cancer | Shanghai University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 3 | NCT01158170 Background | Jun 2010 → May 2013 | non-small cell lung carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01017874 Comparator | Nov 2009 → Apr 2013 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | Missed primary |
| Phase 3 | NCT01024413 Comparator | Jul 2009 → Jun 2015 | neoplasm of thorax | Chinese Society of Lung Cancer | Completed | No outcome recorded |
| Phase 3 | NCT00955695 Background | May 2009 → ? | lung cancer | National Cancer Center, Korea | Unknown | No outcome recorded |
| Phase 3 | NCT01040780 Comparator | Feb 2009 → Mar 2010 | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT00352079 Comparator | Jan 2007 → Jan 2012 | bladder transitional cell carcinoma | NCIC Clinical Trials Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04401059 Comparator | Nov 2020 → Sep 2025 | adenocarcinoma, non-small cell lung carcinoma | Tian Xie | Unknown | No outcome recorded |
| — | NCT04007835 Background | Jul 2019 → Jul 2021 | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Unknown | No outcome recorded |
| — | NCT03602027 Background | Aug → Dec 2018 | non-small cell lung carcinoma | Second Affiliated Hospital of Nanchang University | Unknown | No outcome recorded |
| — | NCT03071705 Background | Mar 2016 → Apr 2017 | lung adenocarcinoma | National Cancer Institute of Mexico | Unknown | Met primary |
| — | NCT02701231 Background | Nov 2015 → Dec 2020 | lung cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| — | NCT02208583 Comparator | Jun 2014 → Dec 2016 | hormone-resistant prostate carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT01776684 Background | Jun 2012 → May 2014 | lung cancer | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT01363557 Background | Mar → Aug 2012 | lung adenocarcinoma, metastatic malignant neoplasm in the brain | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 22
| Date | Issuer | Release |
|---|---|---|
| 2022-03-01 | Lotus Pharmaceutical | Regulatory Lotus obtained marketing authorizations for Lenalidomide and Gefitinib in Philippines lotuspharm.com ↗
Lotus Pharmaceutical (1795:TT), a multinational pharmaceutical company, today announced that the Company’s Lenalidomide (generic version of Revlimid®) and Gefitinib (generic version of Iressa®) have been approved in Philippines. |
| 2019-02-15 | Upsher-Smith Laboratories | Regulatory Sawai Receives Approvals for Three Generic Drugs with Six Strengths upsher-smith.com ↗
Osaka, Japan – February 15, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for three compounds with six strengths of generic drugs. |
| 2018-10-19 | AstraZeneca | Results New data on mechanisms of acquired resistance after 1st-line Tagrisso in NSCLC support initiation of ORCHARD trial to explore post-progression treatment options astrazeneca.com ↗
For the comparator EGFR-TKI arm, the most frequent acquired resistance mechanism to erlotinib or gefitinib was the EGFR T790M mutation (47%). |
| 2018-09-05 | Lotus Pharmaceutical | Regulatory Lotus obtained European approval of Gefitinib, a generic IRESSA®, for multiple European countries as first wave generics lotuspharm.com ↗
Lotus Pharmaceutical announced that it has successfully concluded registration procedures for Gefitinib 250mg tablets in multiple European markets for its generic version of Astra Zeneca’s IRESSA®. |
| 2018-09-05 | Alvogen Korea | Regulatory Alvogen obtains European approvals for generic Gefitinib alvogen.com ↗
Alvogen received regulatory clearance for its product in several European countries and is among the first companies in Europe to obtain approval. |
| 2018-06-04 | Pfizer | Results Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations pfizer.com ↗
The trial showed a median OS of 34.1 months for patients receiving dacomitinib (95% CI: 29.5, 37.7), representing a more than seven-month improvement compared to 26.8 months with gefitinib (95% CI: 23.7, 32.1). |
| 2017-10-17 | Hutchison Medipharma Limited | Results Chi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification hutch-med.com ↗
In both trials, the addition of savolitinib (600mg, once daily), an investigational selective inhibitor of mesenchymal epithelial transition factor (“c-MET”) receptor tyrosine kinase, to Tagrisso® (80mg, once daily) or Iressa® (250mg, once daily) demonstrated preliminary anti-tumor activity. |
| 2017-10-16 | Hutchison Medipharma Limited | Results Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer hutch-med.com ↗
Preliminary data from this Phase II proof-of-concept trial, the first study assessing combining fruquintinib with another tyrosine kinase inhibitor, demonstrated promising efficacy and an acceptable safety profile. |
| 2017-04-07 | Hutchison Medipharma Limited | Results Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017 hutch-med.com ↗
In NSCLC xenograft models with EGFR activation such as activating mutations, gene amplification or protein overexpression, fruquintinib plus an EGFR tyrosine kinase inhibitor such as gefitinib or theliatinib (HMPL-309) was found to be more efficacious than either monotherapy. |
| 2016-10-09 | Boehringer Ingelheim | Results Overall survival data from LUX-Lung 7 head-to-head trial of Gilotrif® (afatinib) versus Iressa® (gefitinib) presented at ESMO prnewswire.com ↗
The median survival of patients treated with afatinib was 27.9 months compared to 24.5 months for those receiving gefitinib, without reaching significance. |
| 2016-06-06 | Novartis Pharmaceuticals | Results Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer novartis.com ↗
The INC280 (capmatinib) data, from a Phase I, single agent study (NCT01324479) in patients with advanced cMET+ NSCLC and a Phase Ib/II combination study (NCT01610336) with gefitinib in patients with EGFR-mutated, cMET+ NSCLC, demonstrated encouraging early signs of clinical activity[4],[5]. |
| 2016-04-13 | Boehringer Ingelheim | Results Head-to-head study demonstrating Gilotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology prnewswire.com ↗
Results from the LUX-Lung 7 trial showed that afatinib significantly reduced the risk of lung cancer progression by 27% versus gefitinib. |
| 2015-07-13 | AstraZeneca | Regulatory IRESSA approved by US FDA for first-line treatment of patients with advanced EGFR mutation-positive non-small cell lung cancer astrazeneca.com ↗
The FDA approval of IRESSA is based on data from the Phase IV IFUM1 (IRESSA Follow-Up Measure) study, assessing IRESSA as a first-line treatment for Caucasian patients with locally advanced or metastatic EGFR mutation-positive NSCLC. |
| 2015-06-02 | AstraZeneca | Results AstraZeneca updates on immuno-oncology combinations development programme at the 2015 ASCO Annual Meeting astrazeneca.com ↗
MEDI4736 and Iressa – early data in EGFRm TKI-naïve NSCLC shows a 64% (9/14) partial response rate. |
| 2015-05-30 | AstraZeneca | Results AstraZeneca and MedImmune present positive immuno-oncology combination data at the 2015 ASCO Annual Meeting astrazeneca.com ↗
Dose escalation data from a Phase I study of MEDI4736 in combination with Iressa (gefitinib), AstraZeneca’s epidermal growth factor receptor (EGFR) mutation positive tyrosine kinase inhibitor (TKI) in advanced NSCLC showed that treatment was generally well tolerated, with early treatment activity in heavily pre-treated patients. |
| 2014-12-02 | AstraZeneca | Regulatory New Drug Application for IRESSA accepted by US Food and Drug Administration astrazeneca.com ↗
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for IRESSA® (gefitinib) as a targeted monotherapy for the first line treatment of patients with advanced or metastatic epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC), as identified through a companion diagnostic test. |
| 2014-09-29 | AVEO Pharmaceuticals, Inc. | Results AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress aveooncology.com ↗
The results, presented in a poster session (abstract #8195) at the 2014 Congress of the European Society for Medical Oncology (ESMO), suggest that VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone. |
| 2014-09-26 | AstraZeneca | Regulatory IRESSA receives CHMP positive opinion to include blood based diagnostic testing in European label astrazeneca.com ↗
AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on a Type-II variation update* to the European label for IRESSA® (gefitinib). |
| 2012-06-07 | Betta Pharmaceuticals Co., Ltd. | Results 凯美纳再次在ASCO上引起国际肿瘤界的关注 bettapharma.com ↗
与PFS结果一样，不管是EGFR突变阳性或者突变阴性的肺癌患者中，凯美纳在最终的OS方面与易瑞沙相当，凯美纳vs易瑞沙分别为20.9月vs 20.2月和7.8月vs 6.9月。 |
| 2011-06-02 | AVEO Pharmaceuticals, Inc. | Results AVEO’s Ficlatuzumab in Combination with Gefitinib Well Tolerated in Patients with Non-Small Cell Lung Cancer; Phase 1b Data Presented at ASCO aveooncology.com ↗
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib (Iressa(TM)) in Asian subjects with non-small cell lung cancer (NSCLC). |
| 2009-07-01 | AstraZeneca | Regulatory IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe astrazeneca.com ↗ |
| 2009-04-23 | AstraZeneca | Regulatory IRESSA (Gefitinib) Recommended for Approval for the Treatment of Non-Small Cell Lung Cancer in Europe astrazeneca.com ↗
The CHMP has recommended the approval of IRESSA for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK (epidermal growth factor receptor-tyrosine kinase), in all lines of therapy. |
All press releases naming this drug 26 releases
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 357 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gefitinib | “Participants with epidermal growth factor receptor (EGFR) gene mutation will receive a drug called Gefitinib, which inhibits a protein called EGFR that is thought to be a key...” NCT02208583 ↗309“This is a phase I study of MK2206 (an AKT inhibitor)and gefitinib in nonsmall cell lung cancer patients who failed prior chemotherapy and epidermal growth factor...” NCT01147211 ↗ “Patients were randomly allocated to receive EGFR-TKIs (erlotinib hydrochloride, afatinib dimaleate, or gefitinib at standard dosage) plus metformin hydrochloride (500 mg twice...” PMID 31486833 ↗ Nov 2019 “The purpose of this protocol is to estimate the maximum tolerated dose of gefitinib in combination with fixed dose of irinotecan and vincristine in patients with refractory...” NCT00186979 ↗ “This study aims to determine effectiveness of Gefitinib (Iressa) in recurrent glioblastoma after standard treatment (surgery, radiationtherapy and at least a first line chemotherapy).” NCT00250887 ↗ “Gefitinib is an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has been widely used for the treatment of non-small cell lung cancer (NSCLC).” PMID 22237124 ↗ Jan 2012 “Combination Anastrozole-ZD1839 (Gefitinib, IRESSA™) in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer” NCT00077025 ↗ “Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc.” NCT04401059 ↗ “Gefitinib blocks the function of epidermal growth factor receptor which is a key factor in stimulating liver cancer growth.” NCT00282100 ↗ “Standard EGFR-TKI(Gefitinib, erlotinib or icotinib) Gefitinib: 250mg po Qd Erlotinib: 150mg po Qd Icotinib: 125mg po tid” NCT03595644 ↗ “Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.” NCT03119519 ↗ |
| Known as | CTTQ | “Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.” NCT03264794 ↗ |
| Known as | GEF | “with the EGFR signaling inhibitor gefitinib (GEF) combined with weekly intravenous paclitaxel (PAC) and radiation therapy (RT).” PMID 19879702 ↗ Oct 2009 |
| Known as | Gefitinib (Iressa) | “Gefitinib (Iressa)” NCT01749072 ↗ |
| Known as | Gefitinib mylan | ChEMBL registry synonym — accepted as the source's own label CHEMBL939 ↗ |
| Known as | GFT | “patients with BM from NSCLC were randomly assigned to 30Gy WBRT with either concomitant gefitinib (GFT) 250mg/day continuously or temozolomide (TMZ) 75mg/m(2) for 21/28days.” PMID 22093943 ↗ Nov 2011 |
| Known as | Iressa | “PURPOSE: This phase II trial assessed the activity and tolerability of a daily oral dose of 500 mg gefitinib (ZD1839, Iressa) in patients with recurrent or persistent...” PMID 16061871 ↗ Aug 200560“A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally...” NCT00076388 ↗ “A Randomised, Open Label, Parallel Group, Multi-Centre, Phase II Study of Progression Free Survival Comparing ZD1839 (IRESSA™) (250 MG Tablet) Versus Vinorelbine (30 MG/M2...” NCT00256711 ↗ “A Phase I/II Trial of Induction Chemotherapy Plus Gefitinib (Iressa) Followed by Concurrent Chemotherapy, Radiation Therapy, and Gefitinib (Iressa) For Patients With Locally...” NCT00193284 ↗ “Randomised Placebo-controlled Phase II Trial of Preoperative Therapy With Gefitinib (Iressa®/ZD1839) and Epirubicin-Cyclophosphamide in Patients With Primary Operable (T2-T3)...” NCT00239343 ↗ “An EORTC Randomized, Double Blind, Placebo-Controlled, Phase II Multi-Center Trial Of Anastrozole (Arimidex) In Combination With ZD 1839 (Iressa) Or Placebo In Patients With...” NCT00066378 ↗ “Phase II Pilot Study of Clinical Activity and Proteomic Pathway Profiling of the EGFR Inhibitor, ZD1839 (Iressa; Gefitinib), in Patients With Epithelial Ovarian Cancer or...” NCT00049556 ↗ “This study aims to determine effectiveness of Gefitinib (Iressa) in recurrent glioblastoma after standard treatment (surgery, radiationtherapy and at least a first line chemotherapy).” NCT00250887 ↗ “A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin” NCT00423397 ↗ “Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer” NCT00090675 ↗ “A Randomized Phase III Study of Follow Up With or Without Adjuvant Gefitinib (Iressa™) Following Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer” NCT00091156 ↗ |
| Known as | Iressa TM | “The purpose of the study is to determine the efficacy of gefitinib (IressaTM) in combination with radiotherapy on patients with glioblastoma multiforme.” NCT00238797 ↗2“A Phase I Study Of ZD1839 (Iressa TM), An Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, In Children With Refractory Solid Tumors” NCT00040781 ↗ “Gefitinib (Iressa TM) Arm - Gefitinib administration 250mg tablet once daily every 3 weeks” NCT00455936 ↗ |
| Known as | NSC-759856 | ChEMBL registry synonym — accepted as the source's own label CHEMBL939 ↗ |
| Known as | Yi Ruisha | “Gefitinib tablets (Yi Ruisha），First medication,250mg；” NCT03264794 ↗ |
| Known as | ZD1839 | “PURPOSE: This phase II trial assessed the activity and tolerability of a daily oral dose of 500 mg gefitinib (ZD1839, Iressa) in patients with recurrent or persistent...” PMID 16061871 ↗ Aug 200553“A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally...” NCT00076388 ↗ “A Randomised, Open Label, Parallel Group, Multi-Centre, Phase II Study of Progression Free Survival Comparing ZD1839 (IRESSA™) (250 MG Tablet) Versus Vinorelbine (30 MG/M2...” NCT00256711 ↗ “The purpose of this study is to determine if the addition of ZD1839 Iressa™ to standard treatment with Casodex® (bicalutamide) for locally advanced prostate cancer can detect a...” NCT00319787 ↗ “Randomised Placebo-controlled Phase II Trial of Preoperative Therapy With Gefitinib (Iressa®/ZD1839) and Epirubicin-Cyclophosphamide in Patients With Primary Operable (T2-T3)...” NCT00239343 ↗ “A Phase II Open-Label Multicentre Study Of The Efficacy Of ZD1839 (IRESSA™) In Combination With Irradiation Followed By Chemotherapy In Patients With Inoperable Stage III Non...” NCT00333294 ↗ “An EORTC Randomized, Double Blind, Placebo-Controlled, Phase II Multi-Center Trial Of Anastrozole (Arimidex) In Combination With ZD 1839 (Iressa) Or Placebo In Patients With...” NCT00066378 ↗ “Over the last three years, the FDA has approved two drugs for salvage treatment of NSCLC, gefitinib (Iressa ®, formerly known as ZD1839) and erlotinib (Tarceva ®, formerly...” NCT00809237 ↗ “Phase II Pilot Study of Clinical Activity and Proteomic Pathway Profiling of the EGFR Inhibitor, ZD1839 (Iressa; Gefitinib), in Patients With Epithelial Ovarian Cancer or...” NCT00049556 ↗ “This is a phase II window study of the combination of ZD1839 (gefitinib) and irinotecan in children with high-risk neuroblastoma followed by standard induction chemotherapy” NCT00135135 ↗ “Combination Anastrozole-ZD1839 (Gefitinib, IRESSA™) in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer” NCT00077025 ↗ |
| Known as | ZD1839, gefitinib (Iressa) | “ZD1839, gefitinib (Iressa)” NCT00052169 ↗ |
| Action | Inhibit | “ZD 1839 may interfere with the growth factor and stop the tumor from growing.” NCT00006048 ↗ |
| Modality | Small molecule | “An Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)” NCT00052208 ↗ |
| Route | Oral | “higher dose oral ZD 1839” NCT00006048 ↗ |
| Target | EGFR | “In tumor samples, gefitinib did not inhibit activation of its proximal target, EGFR.” PMID 16361624 ↗ Dec 2005 |